OpportunityAnalyzer: RespiratorySyncytialVirus (RSV) OpportunityAnalysisandForecaststo2024 "The Report OpportunityAnalyzer: RespiratorySyncytialVirus (RSV) OpportunityAnalysisandForecaststo2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. MarketResearchReports.biz" Human respiratory syncytial virus (RSV) is an enveloped, singlestranded, negativesense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, in infants. RSV is also an important cause of hospitalizations and deaths in elderly adults. Today, Medimmunes Synagis (palivizumab) is the only licensed intervention for the prevention of RSV in infants at a high risk of severe infection. This humanized, mouse monoclonal antibody (mAb) was first approval in 1998, and while it is an efficacious prophylactic intervention, its short 20day halflife necessitates monthly dosing during the RSV season. Moreover, the high cost of Synagis limits its use to certain subgroups of infants who are at high risk of severe RSV infection, and it is not indicated for use in elderly adults, leaving a key population of highrisk individuals unprotected. Furthermore, due to the absence of effective RSVspecific antivirals, the treatment of RSV infections is largely restricted to a number of supportive treatment options. GlobalData projects the global RSV marketplace which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) to experience unprecedented growth from 20142024, driven by the arrival of novel approaches to prevention and management of RSV. Download Sample copy of this Report at http://www.marketresearchreports.biz/sample/sample/699481 Highlights Key Questions Answered Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the RSV marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (20142024)?